CN100379742C - 用作ltd4拮抗剂的新型三环衍生物 - Google Patents

用作ltd4拮抗剂的新型三环衍生物 Download PDF

Info

Publication number
CN100379742C
CN100379742C CNB2003801085261A CN200380108526A CN100379742C CN 100379742 C CN100379742 C CN 100379742C CN B2003801085261 A CNB2003801085261 A CN B2003801085261A CN 200380108526 A CN200380108526 A CN 200380108526A CN 100379742 C CN100379742 C CN 100379742C
Authority
CN
China
Prior art keywords
dihydro
pyridine
alkyl
sulfenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801085261A
Other languages
English (en)
Chinese (zh)
Other versions
CN1735618A (zh
Inventor
C·普伊赫杜兰
D·佩雷斯克雷斯波
J·巴赫塔纳
H·赖德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32309630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100379742(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Publication of CN1735618A publication Critical patent/CN1735618A/zh
Application granted granted Critical
Publication of CN100379742C publication Critical patent/CN100379742C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Paints Or Removers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
CNB2003801085261A 2002-11-12 2003-11-11 用作ltd4拮抗剂的新型三环衍生物 Expired - Fee Related CN100379742C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202590A ES2211315B1 (es) 2002-11-12 2002-11-12 Nuevos compuestos triciclicos.
ES200202590 2002-11-12

Publications (2)

Publication Number Publication Date
CN1735618A CN1735618A (zh) 2006-02-15
CN100379742C true CN100379742C (zh) 2008-04-09

Family

ID=32309630

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801085261A Expired - Fee Related CN100379742C (zh) 2002-11-12 2003-11-11 用作ltd4拮抗剂的新型三环衍生物

Country Status (19)

Country Link
US (1) US7557212B2 (https=)
EP (1) EP1560834B1 (https=)
JP (1) JP2006508116A (https=)
KR (1) KR20050074605A (https=)
CN (1) CN100379742C (https=)
AT (1) ATE399170T1 (https=)
AU (1) AU2003288032A1 (https=)
BR (1) BR0315462A (https=)
CA (1) CA2505491A1 (https=)
CO (1) CO5700775A2 (https=)
DE (1) DE60321810D1 (https=)
EC (1) ECSP055844A (https=)
ES (2) ES2211315B1 (https=)
MX (1) MXPA05005017A (https=)
NO (1) NO20052858L (https=)
RU (1) RU2330855C2 (https=)
UA (1) UA80996C2 (https=)
WO (1) WO2004043966A1 (https=)
ZA (1) ZA200503806B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ATE474601T1 (de) 2004-05-31 2010-08-15 Almirall Sa Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
RU2408584C2 (ru) 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы
JP2009513580A (ja) * 2005-10-21 2009-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CA2842881A1 (en) 2011-07-26 2013-04-11 Rajendrasinh RATHOD Cysteinyl leukotriene antagonists
JP2019081709A (ja) * 2016-03-18 2019-05-30 石原産業株式会社 有害生物防除剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1117730A (zh) * 1993-02-16 1996-02-28 宇部兴产株式会社 喹啉衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411048A1 (en) * 1988-04-28 1991-02-06 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
CZ298578B6 (cs) * 1997-11-25 2007-11-14 Schering Corporation Heterocyklickou skupinou substituovaná tricyklická sloucenina a farmaceutický prostredek ji obsahující
US20030216571A1 (en) * 1999-12-28 2003-11-20 Yoshiaki Kuroki Tricyclic compounds
JP2006151809A (ja) * 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1117730A (zh) * 1993-02-16 1996-02-28 宇部兴产株式会社 喹啉衍生物

Also Published As

Publication number Publication date
EP1560834B1 (en) 2008-06-25
ZA200503806B (en) 2006-08-30
ES2306906T3 (es) 2008-11-16
EP1560834A1 (en) 2005-08-10
ES2211315A1 (es) 2004-07-01
WO2004043966A1 (en) 2004-05-27
CN1735618A (zh) 2006-02-15
ECSP055844A (es) 2005-09-20
NO20052858L (no) 2005-08-12
CO5700775A2 (es) 2006-11-30
BR0315462A (pt) 2005-08-23
ATE399170T1 (de) 2008-07-15
UA80996C2 (en) 2007-11-26
NO20052858D0 (no) 2005-06-13
JP2006508116A (ja) 2006-03-09
MXPA05005017A (es) 2005-08-03
KR20050074605A (ko) 2005-07-18
US7557212B2 (en) 2009-07-07
DE60321810D1 (de) 2008-08-07
AU2003288032A1 (en) 2004-06-03
RU2005118757A (ru) 2006-02-27
RU2330855C2 (ru) 2008-08-10
CA2505491A1 (en) 2004-05-27
ES2211315B1 (es) 2005-10-16
US20060116363A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
US10941160B2 (en) Bromodomain inhibitors
CN100379742C (zh) 用作ltd4拮抗剂的新型三环衍生物
JP5766708B2 (ja) ブロモドメイン阻害剤としてのイミダゾ［４，５−ｃ］キノリン誘導体
US10494371B2 (en) Bromodomain inhibitors
JP5524343B2 (ja) ベンゾジアゼピンブロモドメイン阻害剤
EP1928457B1 (en) Quinolines and their therapeutic use
EP1458718B1 (en) Quinolinones as prostaglandin receptor ligands
US5236937A (en) Pyridinyl compounds which are useful as angiotensin ii antagonists
CN102131798A (zh) 用作磷酸二酯酶10抑制剂的二取代的苯基化合物
KR20120097508A (ko) 벤조디아제핀 브로모도메인 억제제
JPH04505161A (ja) ジアジン誘導体
KR20030043994A (ko) 나프탈렌 유도체
WO2007144625A1 (en) 2-oxo-2h-chromene compounds
WO2009060209A1 (en) 6,6-fused bicyclic aromatic compounds and their therapeuti use
SK32597A3 (en) 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives
CZ20033519A3 (en) Dibenzocycloheptene compound
AU2114600A (en) Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
WO2010040989A1 (en) Quinolin-2-one compounds
WO2016110237A1 (zh) α-咔啉类化合物，其制备方法以及用途
CZ352996A3 (en) Quinoline derivatives, process of their preparation and pharmaceutical compositions based thereon
HK40113493A (zh) 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
JPS6320430B2 (https=)
NZ539954A (en) New tricyclic derivatives as LTD4 antagonists
CN101222924A (zh) 作为促生长素抑制素sst1受体拮抗剂的取代的哌啶衍生物
HK1143372A (en) Quinoline derivatives as crth2 receptor ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080409

Termination date: 20101111